Award Winning Technology
Our next-generation radiopharmaceutical technology has been recognized by many prestigious organizations and we have received numerous awards and grants including:
2021
National Institutes of Health (National Cancer Institute)
Second year renewal of a $2 million Phase II SBIR grant awarded to advance image-guided alpha-particle therapy for metastatic melanoma and radioisotope production technologies
National Institutes of Health (National Cancer Institute)
Second year of a $2 million Phase II SBIR funding to begin a Phase 1 clinical imaging trial of complementary Pb-203 and Ga-68 diagnostics for metastatic melanoma
2019
National Institutes of Health (National Cancer Institute)
$2 million Phase II SBIR grant to fund development activities and advance preclinical studies of VMT-?-NET for neuroendocrine tumors and radionuclide production technologies
National Institutes of Health
$2 million Phase II SBIR grant to support Phase 1 study at Mayo Clinic
National Institutes of Health
$300 thousand Phase I SBIR grant to support preclinical development
2017
National Institutes of Health (National Cancer Institute)
$2 million Phase II SBIR NCI contract to support preclinical development
